Israel-based BGN Technologies has partnered with Singaporean medical diagnostics maker Biosensorix for the development of next-generation diagnostics for point-of-care.

As part of the partnership, the firm will leverage the research performed at Israeli Ben-Gurion University (BGU), which created an electrochemical lateral flow immunosensor in the form of a smart drive that is similar to a USB.

The sensor has been designed to carry out a quantitative diagnosis of biomarkers and pathogens associated with diseases.

BGU Technologies Avram and Stella Goldstein-Goren department Biotechnology Engineering professor Robert Marks said: “There are fast-acting testing kits today that can be used both in the clinic and at home to diagnose a wide range of conditions and diseases, but none of them can discern the severity of the condition or disease.

“In order to determine the severity of a disease, the patient needs to conduct a blood test at a hospital or specialised laboratory, with results taking between half to an entire day, and sometimes even longer.”

“Medical staff will be able to receive immediate results and decide on a course of action.”

Biosensorix has already developed the technology for the diagnosis of dengue hemorrhagic fever.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firms are further advancing the sensor to assess stroke severity and identify a secondary stroke early.

They are formulating the new diagnostic kit to analyse a blood sample for specific biomarkers after an ischemic stroke.

Biosensorix CEO Dr Lukas Fajs said: “At the price range of $5 per kit, our new diagnostic kit presents a breakthrough in diagnosis.

“Medical staff will be able to receive immediate results and decide on a course of action, instead of sending the patient to the lab and waiting for the results.”